SIGN-UP NOW! SIGN-UP NOW! Click to become a VoiceAmerica Member for Free!
Voiceamerica radio logo
voiceamerica-health-and-wellness radio logo
Apple logo Google Play Store Kindle store
C. diff. Spores and More
top banner

C. diff. Spores and More

Tuesday at 10 AM Pacific

May 16th 2017:Synthetic Biologics - Protecting the Gut Microbiome: A Paradigm Shift in Managing GI Disorders

Join us with our guest, Dr. Joseph Sliman, MD, MPH, Chief Medical Officer of Synthetic Biologics as Dr. Sliman discusses the protection of the natural gut microbiome from the unintended consequences of intravenous (IV) antibiotics which are excreted into the gut is expected to protect against opportunistic enteric infections. Synthetic Biologics is developing two microbiome-focused drug candidates in Phase 3 development including, SYN-004 (ribaxamase) which is designed to protect the gut microbiome by degrading certain IV beta-lactam antibiotics for the prevention of Clostridium difficile infe

Read more
Share Email SHARE
Download PDF DOWNLOAD PDF
Get Code GET CODE

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel
LISTEN LIVE
EPISODE ON DEMAND
VIEW HOST PAGE
Questions? Comments?
Call In Live!
Toll Free: 1-866-472-5792
Intl: 001-480-553-5759

Featured Guest

Guest Image

Dr Joseph Sliman MD

Dr. Sliman, MD, MPH, Chief Medical Officer joined Synthetic Biologics in January 2013 as the Senior Vice President, Clinical & Regulatory Affairs. In this position, Dr. Sliman will be responsible for the design and implementation of all aspects of clinical development, including clinical trials, and will lead the Company’s regulatory initiatives. During his service in the United States Navy, Dr. Sliman led the U. S. Pacific Fleet disease surveillance programs, including influenza surveillance, preparedness, and prevention, as well as communicable disease and injury surveillance and prevention and health policy development. Dr. Sliman earned an M.D. from the Uniformed Services University,
Read more

Share This Episode

facebook Share On Facebook
twitter Share On Twitter
Linkedin Share On LinkedIn
Share Email Share this E-mail
https://www.voiceamerica.com/show/2441/c-diff-spores-and-more 24/10/2017 10:00 24/10/2017 11:00 C. diff. Spores and More https://www.voiceamerica.com/show/2441/c-diff-spores-and-more Join us with our guest, Dr. Joseph Sliman, MD, MPH, Chief Medical Officer of Synthetic Biologics as Dr. Sliman discusses the protection of the natural gut microbiome from the unintended consequences of intravenous (IV) antibiotics which are excreted into the gut is expected to protect against opportunistic enteric infections. Synthetic Biologics is developing two microbiome-focused drug candidates in Phase 3 development including, SYN-004 (ribaxamase) which is designed to protect the gut microbiome by degrading certain IV beta-lactam antibiotics for the prevention of Clostridium difficile infection (CDI), pathogenic overgrowth and the emergence of antimicrobial resistance, and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). VoiceAmerica | Talk Radio | Online Talk Radio studio@voiceamerica.com false DD/MM/YYYY Add to Calendar
Email Host Email the Host

Connect with VoiceAmerica

Download our mobile apps
App store Google play Blackberry store
GPlus Facebook Twitter Linkedin Social Media
presspass-banner